ALCL was refractory to the last treatment in 10/15 pts. 10/11 pts had detectable ALK transcript in blood by RT-PCR...After a median follow-up of 1.3 years, 1-year PFS and OS were 72% and 85%, respectively...Brigatinib showed high efficacy, including in pts who have failed crizotinib, and was well tolerated.

ALCL was refractory to the last treatment in 10/15 pts. 10/11 pts had detectable ALK transcript in blood by RT-PCR. Pts received brigatinib at a dose of 180 mg once daily….Brigatinib showed high efficacy, including in pts who have failed crizotinib, and was well tolerated.

For all three PDXs, significant increases in EFS were seen for tumour-bearing animals treated with brigatinib relative to vehicle (MGS-A-x: p = 0.02494, MTK-A-x: p = 0.048, GR-ALCL-1: p = 0.01299; Figure 3G–I), with 3/8, 5/8 and 5/8 mice, respectively, showing a reduction in tumour volume (Figure 3D–F). Brigatinib treatment also led to a significant increase in EFS relative to crizotinib-treated mice...these data suggest that brigatinib administration is a well-tolerated approach for the treatment of PDX derived from ALK-positive ALCL involving the CNS that is either sensitive or r/r to crizotinib.